ACAnne-Marie Carreau

Anne-Marie Carreau

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anne-Marie Carreau has a total of 171 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Muscle and intra-pancreatic fat deposition in relation to glucose metabolism in individuals at high risk for type 2 diabetes

    by Ana Berteaux, Théo Gignac, Sandrine Beaulieu, Claudia Gagnon, Éric Larose, Marie-Claude Vohl, André Marette, Anne-Marie Carreau

    Aims/hypothesis: We investigated the association between multi-organ ectopic fat and glucose metabolism in individuals at high risk for type 2 diabetes. We aimed to better understand subclinical alterations in insulin secretion and sensitivity, and their relation to intra-pancreatic and postural muscle fat while adjusting for hepatic fat. Methods: This cross-sectional study included 80 individuals with a BMI between 23 and 40 kg/m 2 and at least one metabolic alteration: increased fasting triglycerides or insulin, plasma glucose, HbA 1c and/or high waist circumference. Participants underwent abdominal MRI and a 3 h 75 g OGTT. Ectopic fat in the liver, pancreas and psoas and paraspinal muscles was quantified using mDIXON. Insulin sensitivity, insulin secretion and pancreatic beta cell function were determined with the oral minimal model. Results: The median age of participants was 56 (IQR 39–64) years and 63% were women. Pancreatic fat fraction and paraspinal muscle fat fraction did not correlate with glucose metabolism indices. Psoas muscular fat fraction was negatively associated with static insulin secretion ( r = − 0.23, p = 0.04) and static disposition index ( r = − 0.23, p = 0.04) and positively associated with HOMA2-IR ( r = 0.25, p = 0.03), independent of age, sex and BMI. The associations did not remain significant when adding hepatic fat as a covariable. Conclusions/interpretation: These results suggest that intra-pancreatic and postural muscle fat are not associated with insulin secretion and resistance in individuals at risk for type 2 diabetes. Liver fat could be a main contributor of early risk for type 2 diabetes development.

  • Fasting Hormonal and Inflammatory Profiles according to Liver Fibrosis Stages in Metabolic Dysfunction-Associated Steatotic Liver Disease

    by Ana Berteaux, Marion Pradeau, Julie-Catherine Coll, Stéphanie Ferland, Anne-Marie Carreau

    Endocrine mechanisms underlying progression of metabolic dysfunction-associated steatotic liver disease (MASLD) to advanced fibrosis remain unclear. We aimed to characterize fasting hepatokines, adipokines, gastrointestinal hormones, and inflammatory markers according to fibrosis stages in MASLD and explore their associations with glucose and lipid metabolism. In this cross-sectional study, 79 individuals with MASLD were grouped into no evidence of advanced fibrosis (no-AF; F0-F2) (n=51) and advanced fibrosis (AF; F3-F4) (n=28). Fasting plasma levels of hepatokines (ANGPTL3, ANGPTL4, ANGPTL6, and FGF-21), adipokines (leptin), gastrointestinal hormones (GLP-1, GIP, glucagon, and FGF-19), and inflammatory markers (TNF-α, IL-6, and MCP-1) were measured. Spearman correlations between hormones and indices of glucose and lipid metabolism were calculated and further adjusted for age, sex, and BMI. Median age (56[44-64] vs. 56[48-65] yr), sex (57 vs. 39% women), and BMI (33[27-37] vs. 34[31-38] kg/m 2 ) were comparable between groups. Individuals with AF had lower ANGPTL6 (p=0.03) and higher IL-6 (p=0.02) and TNF-α (p<0.0001), whereas other hepatokines, leptin, and gastrointestinal hormones were similar between groups. Independently of age, sex, and BMI, ANGTL6 was positively associated with triglycerides (r=0.44, p<0.01). GIP and glucagon were strongly associated with hepatic and adipose tissue insulin resistance and reduced β-cell function (p≤0.003). Additionally, FGF-19 was negatively associated with hepatic insulin sensitivity (r=-0.26, p=0.02) and positively associated with insulin secretion (r=0.27, p=0.02). Overall, our results suggest that advanced fibrosis is characterized by selective reduction of ANGPTL6 and increased inflammatory markers rather than global endocrine alterations. Gastrointestinal hormones could be major contributors of impaired fasting glucose metabolism in MASLD.

  • Open Access

    Metabolomic and lipidomic plasma profiles according to metabolic dysfunction-associated steatotic liver diseases (MASLD) stages in the absence of type 2 diabetes (T2D).

    by Marion Pradeau, Julie-Catherine Coll, Ana Berteaux, Véronique Paquet, Isabelle Robillard Frayne, Stéphanie Ferland, Matthieu Ruiz, Anne-Marie Carreau

    Introduction: : Amino acids (AAs), tricarboxylic acid (TCA) cycle intermediates, and acylcarnitines (ACs) can reflect energetic metabolism. Metabolic dysfunction-associated steatotic liver (MASLD) has been associated with the modification of plasma AAs, ACs and TCA cycle intermediates’ profiles, but the changes in advanced fibrosis without type 2 diabetes (T2D) are not well studied. Objectives: The objective of this pilot study was to describe the targeted plasma metabolomic profile in individuals with advanced fibrosis to test research hypotheses concerning hepatic energy metabolism. Methods: We compared plasma fasting concentrations of 21 AAs, 11 organic acids (including ketone bodies and TCA cycle intermediates) and 14 ACs between individuals with advanced fibrosis stages (F3-F4/4) ( n = 10) and individuals with no advanced fibrosis ( n = 10), all without T2D and with similar clinical characteristics. Results: Median age (IQR) (51 [43–67] vs. 57 [43–66] years), sex (30 vs. 50% men) and BMI (35 [28–37] vs. 37 [32–39] kg/m 2 ) were comparable between groups. The advanced fibrosis (AF) group presented higher plasma tyrosine ( p = 0.04), α-ketoglutarate ( p = 0.04), and a lower level of medium-chain ACs C8 and C10 ( p = 0.04). The glutamate-glycine-serine (GSG) index, which combines AAs involved in glutathione metabolism, was higher in the AF group ( p = 0.04). Conclusion: Overall, our results suggest impaired AAs catabolism and mitochondrial dysfunction. While the limited sample size and study design preclude causal inferences, these findings highlight potential metabolic signatures of advanced fibrosis in MASLD. They also underscore the need for larger, longitudinal studies to clarify their origin, significance, and clinical implications.

  • Plasma and fecal bile acids profiles in metabolic dysfunction-associated steatotic liver disease with advanced fibrosis

    by Marion Pradeau, Sandrine Beaulieu, Véronique Paquet, Jocelyn Trottier, Mélanie Verreault, Stéphanie Ferland, Olivier Barbier, Anne-Marie Carreau

    This study explored detailed plasma and fecal concentrations of 35 bile acids in MASLD with advanced fibrosis. Total, primary, and secondary plasmatic bile acids, particularly the CDCA family, were increased in advanced fibrosis without changes in their effectors, FGF-19/GLP-1. This profile may lead to a proinflammatory BA profile. We also showed that novel, unstudied BAs species are of interest in advanced fibrosis, such as glucuronides.


  • Open Access

    A review of multidisciplinary care in metabolic dysfunction‐associated steatohepatitis and cardiometabolic disease, with a focus on Canada

    by James Kim, Paolo Raggi, Anne‐Marie Carreau, Sean Wharton, Alice Y. Y. Cheng, Mark G. Swain

    Cardiometabolic disease (CMD) is associated with an increased risk of metabolic dysfunction‐associated steatohepatitis (MASH). Most patients develop MASH in association with type 2 diabetes and obesity. Optimal disease management requires effective multidisciplinary collaboration between primary care physicians and specialists from different medical fields; however, awareness of the risks, association with CMD, diagnosis, complications, and management strategies of MASH is low among non‐liver specialists. In Canada, variable access to diagnostic testing and, until recently, the lack of national MASH guidelines, are also barriers to effective disease management. Ongoing cross‐disciplinary education and wide systemic changes are required to ensure timely patient identification and the establishment of holistic patient care pathways that can begin to address MASH and associated CMD.


  • Metabolic-associated fatty liver disease is characterized by a post-oral glucose load hyperinsulinemia in individuals with mild metabolic alterations

    by Théo Gignac, Gabrielle Trépanier, Marion Pradeau, Arianne Morissette, Anne-Laure Agrinier, Éric Larose, Julie Marois, Geneviève Pilon, Claudia Gagnon, Marie-Claude Vohl, et al.

    Using an oral glucose tolerance test, we found hyperinsulinemia, lower insulin sensitivity, lower insulin clearance, and lower first-phase pancreatic β-cell function in individuals with MAFLD. This may explain part of the increased risk of incident type 2 diabetes in this population. These data also highlight implications of hyperinsulinemia and impaired insulin clearance in the progression of MAFLD to type 2 diabetes.


  • PROFILE OF PLASMATIC AND FECAL BILE ACIDS ACCORDING TO STAGES OF METABOLIC-ASSOCIATED FATTY LIVER DISEASE

    by P. Marion, S. Beaulieu, T. Jocelyn, F. Stéphanie, B. Olivier, A. Carreau

  • Glycated Hemoglobin Is Suboptimal for the Screening of Prediabetes and Type 2 Diabetes in Adults With Nonalcoholic Fatty Liver Disease

    by Théo Gignac, Gabrielle Trépanier, Véronique Paquet, Stéphanie Ferland, Anne-Marie Carreau


  • Insulin Resistance and Lipotoxicity in PCOS: Causes and Consequences

    by Anne-Marie Carreau, Marie-Claude Battista, Jean-Patrice Baillargeon


  • Good agreement between hyperinsulinemic‐euglycemic clamp and 2 hours oral minimal model assessed insulin sensitivity in adolescents

    by Anne‐Marie Carreau, Danielle Xie, Yesenia Garcia‐Reyes, Haseeb Rahat, Kai Bartlette, Cecilia Diniz Behn, Laura Pyle, Kristen J. Nadeau, Melanie Cree‐Green

    Background/Objective Rates of dysglycemia are increasing in youth, secondary to obesity and decreased insulin sensitivity (IS) in puberty. The Oral Minimal Model (OMM) has been developed in order to measure insulin sensitivity using an easy oral glucose load such as an oral glucose tolerance test (OGTT), instead of an hyperinsulinemic‐euglycemic clamp (HE‐Clamp), a more invasive and time‐consuming procedure. However, this model, following a standard 2h‐ OGTT has never been validated in youth, a population known for a different physiologic response to OGTT than adults. Thus, we compared IS measurements obtained from OMM following a 2h OGTT to HE‐Clamp and isotope tracer‐assessed tissue IS in adolescents. We also compared the liver/muscle‐specific IS from HE‐Clamp with other liver/muscle‐specific IS surrogates following an OGTT previously validated in adults. Methods Secondary analysis of a cross‐sectional study. Adolescent girls with (n=26) and without (n=7) Polycystic Ovary Syndrome (PCOS) (14.6±1.7 years; BMI %ile 23.3%‐98.2%) underwent a 2‐hour 75g OGTT and a 4‐phase HE‐Clamp. OMM IS (Si), dynamic Si (Sid) and other OGTT‐derived muscle and liver IS indices were correlated with HE‐Clamp tissue‐specific IS. Results OMM Si and Sid correlated with HE‐clamp‐measured peripheral IS (r=0.64, p<0.0001 and r=0.73; p<0.0001, respectively) and the correlation co‐efficient trended higher than the Matsuda index (r=0.59; p=0.003). The other tissue specific indices were poorly correlated with their HE‐Clamp measurements. Conclusion In adolescent girls, the 2h OMM provided the best estimate of peripheral IS. Additional surrogates for hepatic IS are needed for youth.